---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-23-000112"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:23:01.303270+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q2 net loss $22.7M; vascular trauma trial enrollment complete, BLA on track

## Summary
- Completed enrollment in Phase 2/3 V005 trauma trial (68 patients, 51 for efficacy); top-line results expected Q3 2023.
- BLA filing for HAV in vascular trauma planned Q4 2023; received RMAT designation in May 2023.
- Cash $114.6M; up to $160M Oberland funding ($40M received); funds operations past potential approval.
- Net loss $22.7M vs net income $36.9M in Q2 2022; increase due to non-cash remeasurement of contingent earnout.
- Ukraine humanitarian program: 19 patients, 95% 30-day patency, 100% limb salvage, 0 infections.

## SEC filing metadata
- accession: 0001818382-23-000112
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/0001818382-23-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/huma-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-23-000112
- JSON: https://secwatch.observer/filing/0001818382-23-000112.json
- Plain text: https://secwatch.observer/filing/0001818382-23-000112.txt

## Key facts
- Earnings Releases
  Humacyte, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/0001818382-23-000112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.